Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a single dose of esketamine stop itching in older surgery patients?

NCT ID NCT07597486

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a low dose of esketamine, given during knee replacement surgery, can reduce itching in elderly patients with senile pruritus. Two hundred participants will receive either esketamine or a placebo, and their itching will be measured over the following week. The goal is to see if this drug can provide relief without major side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Esketamine
What this could lead to
If it works, this could offer a new way to ease severe itching in older adults during and after surgery.
What could go wrong
This is a small, early-stage trial with only 200 participants. It may not show a clear benefit, and esketamine can cause side effects like dizziness or nausea.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Meet the diagnostic criteria for senile pruritus: 1. Aged ≥ 65 years old; 2. Presenting with only skin pruritus without obvious primary skin lesions, with or without scratch-induced skin lesions; 3. Daily or nearly daily pruritus lasting for more than 6 weeks. 2. Patients undergoing elective general anesthesia for orthopedic knee arthroplasty. 3. Patients aged ≥ 65 years old, with ASA physical status classification Ⅰ-Ⅲ; BMI ranging from 18 to 30 kg/m², with no restriction on gender. 4. Patients have fully understood the nature of this study, are capable of understanding and completing evaluation scales preoperatively, voluntarily participate in this trial, and sign the informed consent form. Exclusion Criteria: 1. Those who are allergic to the pharmaceutical ingredients of this study or have an allergic constitution; 2. Those with a history of allergy to general anesthetics, opioids, or non-steroidal anti-inflammatory drugs; 3. Those with severe cognitive impairment, a history of neurological diseases, chronic pain, drug addiction, alcoholism, long-term opioid use, or administration of opioids within 48 hours before surgery; 4. Patients with ASA physical status classification Grade IV-V; 5. Those with severe coronary heart disease/arrhythmia/cardiac insufficiency, bronchial asthma, severe hypertension, severe hematopoietic system dysfunction, severe abnormal liver and kidney function, or significant electrolyte disorders; 6. Those with a history of gastrointestinal diseases (peptic ulcer, Crohn's disease, ulcerative colitis); 7. Those with respiratory insufficiency or respiratory failure; 8. Those with BMI \< 18 kg/m² or BMI \> 30 kg/m²; 9. Those with poor compliance who cannot complete the trial in accordance with the research protocol; 10. Those who have participated in other clinical drug trials within the past 4 weeks; 11. Those deemed unsuitable for enrollment by the researchers for any reason. -

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Senile pruritus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Pruritus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Tianjin Medical University General Hospital

    Tianjin, 300052, China